ArticleRadiation oncology (London, England)2026
Functional lung avoidance proton radiation therapy planning using anatomy-wise computed tomography-derived lung ventilation imaging.
Article in Radiation oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeThis study aimed to assess the dosimetric benefits of functional avoidance proton therapy planning using anatomy-wise computed tomography (CT)-derived lung ventilation imaging (VIaw), which helps spare both high-functioning lung volume (HFV) and recoverable low-functioning lung volume (rLFV) for the first time in proton therapy.
methodsIn a cohort of 18 lung cancer patients, VIaw was generated from planning CT scans. For each patient, we created anatomical and functional-guided intensity-modulated radiation therapy (aIMRT, fIMRT) and proton therapy (aIMPT, fIMPT) plans. For a subset of eight patients with tracheal obstruction by the tumor, we generated two extra rLFV-sparing plans (rfIMRT, rfIMPT) that specifically incorporated constraints to spare both HFV and rLFV.
resultsFor the 18 patients, functional IMPT (fIMPT) demonstrated superior HFV sparing, achieving statistically significant reductions in all HFV dose parameters compared to fIMRT (V5: 34.9%±18.1%; V20: 20.6%±17.0%; V30: 9.6%±17.4%; mean dose: 25.3%±10.5%; all p < 0.05) and additional significant sparing compared to aIMPT. For the eight patients with tracheal obstruction by the tumor, rfIMPT significantly reduced rLFV dose compared to fIMPT (V20: 11.4%±6.2%; V30: 16.4%±5.9%; mean dose: 13.0%±4.7%; all p < 0.05) and showed advantages over rfIMRT, particularly in V5 reduction (4.5%±5.4%, p < 0.05). IMPT plans consistently outperformed IMRT in OAR sparing, reducing contralateral lung mean dose to approximately one-fourth of IMRT levels. Other dosimetric parameters for rfIMPT and fIMPT were comparable and within acceptable limits.
conclusionsIncorporating VIaw into functional proton planning effectively enhanced dose sparing of HFV and rLFV while maintaining excellent OAR protection. This approach demonstrates the potential of proton therapy to simultaneously preserve functional lung regions and facilitate recovery of compromised areas. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.